TeaRx Overview

  • Founded
  • 2011
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Investors
  • 3

TeaRx General Information


Developer of therapeutic drugs intended to prevent deep venous thrombosis (DVT) and pulmonary embolism (PE). The company's drug is a new class of anticoagulants-blood coagulation factor Xa inhibitors and has thioredoxin molecule which is required during treatment of a range of diseases, as well as after the most part of surgical procedures, enabling medical institutions to prevent thromboembolism in patients and save lives.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Khimki 2-d, Rabochaya Street
  • Building 1
  • Moscow, 141400
  • Russia
+7 8 (000) 000-00-00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TeaRx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC Completed Clinical Trials - General
To view TeaRx’s complete valuation and funding history, request access »

TeaRx Board Members (1)

Name Representing Role Since
Savchuk Nikolay Self Chairman 000 0000
To view TeaRx’s complete board members history, request access »

TeaRx Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioLight Life Sciences Corporation Minority 000 0000 000000 0
ChemRar Ventures Venture Capital Minority 000 0000 000000 0
Torrey Pines Investment Venture Capital Minority 000 0000 000000 0
To view TeaRx’s complete investors history, request access »